The Banki Lab | Immunology of Virus Infections

The Banki Lab at the Institute of Virology, MUI, focuses on the immunology of viral infections, with an emphasis on respiratory viruses and oncolytic virotherapy. Our research investigates the intricate interactions between the immune system and viruses, aiming to contribute to the development of effective therapeutic strategies for both infectious and cancer-related diseases.

A key area of our work involves respiratory viruses such as respiratory syncytial virus (RSV), a significant cause of severe respiratory infections, particularly in young children and older adults. By studying the immune mechanisms that govern T cell responses and cytokine production during RSV infections, we aim to better understand the balance between viral clearance and immunopathology.

In addition, our lab conducts studies on oncolytic viruses, specifically vesicular stomatitis virus pseudotyped with LCMV glycoprotein (VSV-GP). Oncolytic viruses hold promise as cancer therapies, leveraging their ability to selectively infect and destroy tumor cells while stimulating anti-tumor immune responses. Our preclinical studies evaluate the immunological effects of VSV-GP, particularly its capacity to activate and sustain T cell responses that target cancer cells.

To achieve these goals, our group employs cutting-edge methodologies, including spectral flow cytometry, to dissect the complexities of immune cell populations and their functional dynamics. This high-resolution approach enables us to gain detailed insights into how viruses shape the immune landscape, from initial infection to resolution or chronicity.

By combining expertise in virology and immunology with advanced technologies, we aim to uncover critical insights into virus-host interactions. Our work seeks to inform the design of novel antiviral therapies, vaccines, and oncolytic virotherapies, ultimately improving outcomes for patients affected by viral infections and cancer.